JUL 22, 2021 5:00 PM EDT

Closing Keynote Presentation Response to Second Generation CAR T Cell Therapy: It takes (at least) Two to Tango

C.E. Credits: Florida CE P.A.C.E. CE
Speaker
  • Professor, Pathology and Laboratory Medicine, University of Pennsylvania and Director, Biomarker Program, Parker Institute for Cancer Immunotherapy, UPenn
    BIOGRAPHY

Abstract

Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this therapy has hit a glass ceiling w.r.t. initial and durable remissions. Inclusion of a costimulatory domain in the CAR design have solved much of limited clinical efficacy issues, some challenges remained. We have recently demonstrated that T cell-intrinsic mechanisms solved part of the glass ceiling conundrum in leukemia, we recently demonstrated that primary chronic lymphocytic leukemia cells elicit a blunted response of second generation CAR T cells, even when using normal donor CAR-engineered T cells. In my talk I will highlight our discoveries in T cell- and tumor-intrinsic determinants of anti-CD19 CAR T cell responses in this disease.

Learning Objectives:

1. Classify the Chimeric Antigen Receptor (CAR)-engineered T cells have dramatically altered the clinical outlook for many blood cancers

2. Identify that with the discovery of costimulation as a critical component of an effective T cell responses and the inclusion of such domains in CAR design we have overcome previous significant roadblocks, but encountered new challenges along the way

3. Recognize the part of what explains response and resistance to this therapy is T cell-intrinsic; however, even the most efficacious CAR showed ineffective against primary tumor cells

4. Summarize the highlights of some of our discoveries in elucidating T cell- and tumor-cell-intrinsic determinants of CAR T cell efficacy


Show Resources
You May Also Like
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
SEP 16, 2021 8:00 AM PDT
C.E. CREDITS
SEP 16, 2021 8:00 AM PDT
Date: September 16, 2021 Time: 8:00am (PDT), 11:00am (EDT) Rapid screening and speed of scale-up in protein therapeutics are critical factors in today’s biotech and pharma workflows. T...
JUN 24, 2021 8:00 AM PDT
C.E. CREDITS
JUN 24, 2021 8:00 AM PDT
Date: June 24, 2021 Time: 8:00am (PDT), 11:00am (EDT) Cardiovascular disease is a leading health problem, affecting almost 30% of individuals in the developed world, and comprises a wide ran...
APR 20, 2021 4:30 PM PDT
C.E. CREDITS
APR 20, 2021 4:30 PM PDT
COVID-19 is a severe disease that has caused >1 million deaths in under one year. As this disease is novel, the molecular and cellular underpinnings of the progressive tissue injury are p...
Loading Comments...
Show Resources